Search results
Results From The WOW.Com Content Network
Liraglutide, sold under the brand name Victoza among others, is an anti-diabetic medication used to treat type 2 diabetes, and chronic obesity. [6] [7] It is a second-line therapy for diabetes following first-line therapy with metformin. [6] [8] Its effects on long-term health outcomes like heart disease and life expectancy are unclear.
Drugs used in diabetes treat types of diabetes mellitus by decreasing glucose levels in the blood.With the exception of insulin, most GLP-1 receptor agonists (liraglutide, exenatide, and others), and pramlintide, all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents.
Victoza, chemically known as liraglutide, is a once-daily injection approved for use in adults and children aged 10 or older with type 2 diabetes. The drug brought in annual sales of $1.66 billion ...
In March 2021, in a phase III randomized, double-blind trial, 1,961 adults with a body mass index of 30 or greater were assigned in a 2:1 ratio to a treatment with once-weekly subcutaneous semaglutide or placebo, plus lifestyle intervention. The trials occurred at 129 sites in 16 countries in Asia, Europe, North America, and South America.
Insulin icodec was approved for medical use in Canada in March 2024. [3]In March 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Awiqli, intended for the treatment of diabetes. [5]
The dose is usually started low and tapered gradually. Some of the common side effects of the medication is nausea, vomiting and diarrhea. Patients with a family history of medullary thyroid cancer or Multiple Endocrine Neoplasia type 2 should not be prescribed the drug may increase the risk of developing cancer .
Download QR code; Print/export Download as PDF; Printable version; In other projects Wikidata item; ... weekly (once a week) This page was last ...
“Unrestricted enrollment of patients at the lower Decoy20 dose will enable us to gather more safety and efficacy data, which is crucial for assessing the full potential of Decoy20. The data will guide how we initiate combination therapy next year, a critical phase in advancing Decoy20,” said Dr. Roger Waltzman, Indaptus Chief Medical Officer.